Evidence Level:Sensitive: A2 - Guideline
New
Title:
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Excerpt:Recommendations:...bortezomib may be considered for patients with high-risk disease [II, B].
DOI:10.1016/j.annonc.2020.11.014
Evidence Level:Sensitive: B - Late Trials
New
Title:
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial
Excerpt:Median progression-free survival was significantly improved in the VRd group (43 months vs 30 months in the Rd group…In patients with newly diagnosed myeloma, the addition of bortezomib to lenalidomide and dexamethasone resulted in significantly improved progression-free and overall survival and had an acceptable risk-benefit profile.
DOI:10.1016/S0140-6736(16)31594-X